RU94034011A - Method for treatment of psychic disturbance
- Google Patents
Method for treatment of psychic disturbance
Info
Publication number
RU94034011A
RU94034011ARU94034011/14ARU94034011ARU94034011ARU 94034011 ARU94034011 ARU 94034011ARU 94034011/14 ARU94034011/14 ARU 94034011/14ARU 94034011 ARU94034011 ARU 94034011ARU 94034011 ARU94034011 ARU 94034011A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by С.В. Санникова, С.С. Островка, Н.А. ПавловаfiledCriticalС.В. Санникова
Priority to RU94034011/14ApriorityCriticalpatent/RU94034011A/en
Publication of RU94034011ApublicationCriticalpatent/RU94034011A/en
FIELD: phychiatry. SUBSTANCE: proposed method makes it possible to completely heal patient from psychic disturbance by purifying patient's brain from "devilish force" parasitically living therein. EFFECT: useful approach for psychiatry.
Claims (1)
Способ предназначен для полного вылечивания человека от психического расстройства посредством очистки мозга больного от паразитирующей в нем "дьявольской силы".The method is intended to completely cure a person of a mental disorder by cleaning the patient’s brain from the "devilish power" parasitizing in it.
RU94034011/14A1994-09-161994-09-16Method for treatment of psychic disturbance
RU94034011A
(en)
Use of 9-deoxy-2',9-methano-3-oxa-4,5,6-trinor-3,7-(1',3'interphenylene)-13,14-dihydroprostaglandin F1 to treat peripheral vascular disease
Method of vomiting treatment or prophylaxis in mammalian and human using the certain quinuclidine, piperidine, azanorbornane, ethylenediamine derivatives and related compounds
Use of L-carnitine and acyl-L-carnitine for the treatment of patients suffering from AIDS-related syndromes and of asymptomatic HIV-seropositive patients
Process for producing pharmaceutical compositions suitable for treating pathological conditions concerning cerebral blood insufficiency and one special active ingredient